A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient
After failure of anthracycline- and platinum-based therapy, no effective therapies exist for management of metastatic triple-negative breast cancer (TNBC). We report a case of metastatic TNBC harboring MCL1 amplification, as identified by comprehensive genomic profiling in the course of clinical car...
Main Authors: | Siraj M. Ali, Jessica Watson, Kai Wang, Jon H. Chung, Caitlin McMahon, Jeffrey S. Ross, Karel A. Dicke |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2016-02-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/443371 |
Similar Items
-
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
by: Radek Lakomy, et al.
Published: (2017-12-01) -
Effets pharmacocinétique et pharmacodynamique de l’association d’everolimus et de sorafénib : l'impact des doses et des schémas d'administration sur la combinaison
by: El Madani, Mévidette
Published: (2017) -
Noxa/Mcl-1 Balance Regulates Susceptibility of Cells to Camptothecin-Induced Apoptosis
by: Yide Mei, et al.
Published: (2007-10-01) -
Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression
by: Jianliang Xu, et al.
Published: (2019-07-01) -
Targeting MCL-1 in cancer: current status and perspectives
by: Haolan Wang, et al.
Published: (2021-04-01)